Is there any difference between PEG-IFN a2a or a2b plus ribavirin for HCV patient in real life conditions.


ŞİRİN G. , Şentürk Ö., ÇELEBİ A. , HÜLAGÜ S.

23rd Annual Conference of APASL, Brisbane, Australia, 12 - 15 March 2014

  • Publication Type: Conference Paper / Summary Text
  • City: Brisbane
  • Country: Australia